7.27

0.97% +0.07

After Hours: 7.27

Aura Biosciences Inc (AURA)

Overview News Price History Option Chain Financials Why AURA Down? Discussions Forecast

Aura Biosciences Inc stock is currently priced at $7.27, with a 24-hour trading volume of 199.04K. It has seen a +0.97% increased in the last 24 hours and a +3.41% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $7.24 pivot point. If it approaches the $7.48 resistance level, significant changes may occur.

Previous Close:

$7.20

Open:

$7.24

24h Volume:

199.04K

Market Cap:

$360.18M

Revenue:

Net Income/Loss:

$-76.41M

P/E Ratio:

-3.635

EPS:

-2

Net Cash Flow:

$-64.56M

1W Performance:

-0.55%

1M Performance:

+3.41%

6M Performance:

-10.25%

1Y Performance:

-36.34%

1D Range:

$6.99

$7.395

52W Range:

$5.99

$13.50

Aura Biosciences Inc Stock (AURA) Company Profile

Name

Aura Biosciences Inc

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

617 500 8864

Address

85 Bolton Street, Cambridge

Employee

Twitter

Next Earnings Date

2024-05-29

Latest SEC Filings

AURA's Discussions on Twitter

Aura Biosciences Inc Stock (AURA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-27-23	Initiated	Scotiabank	Sector Outperform
Apr-17-23	Resumed	BTIG Research	Buy
Jul-19-22	Initiated	JMP Securities	Mkt Outperform

Aura Biosciences Inc Stock (AURA) Latest News

China Petroleum & Chemical (OTCMKTS:SNPMF) Stock Price Down 2.8% - Defense World

Defense World

Vanguard Canadian Long-Term Bond Index ETF (TSE:VLB) Shares Down 0.7% - Defense World

Defense World

Global Beta Smart Income ETF (NYSEARCA:GBDV) Shares Down 1.7% - Defense World

Defense World

Aura Biosciences Inc Stock (AURA) Financials Data

Aura Biosciences Inc (AURA) Net Income 2024

AURA net income (TTM) was -$76.41 million for the quarter ending December 31, 2023, a -30.03% decrease year-over-year.

Aura Biosciences Inc (AURA) Cash Flow 2024

AURA recorded a free cash flow (TTM) of -$64.56 million for the quarter ending December 31, 2023, a -15.91% decrease year-over-year.

Aura Biosciences Inc (AURA) Earnings per Share 2024

AURA earnings per share (TTM) was -$1.92 for the quarter ending December 31, 2023, a +2.04% growth year-over-year.

Aura Biosciences Inc Stock (AURA) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Feder Julie B	Chief Financial Officer	Jan 23 '24	Sale	7.64	6,609	50,521	62,991
Matrix Capital Management Comp	10% Owner	Nov 09 '23	Buy	9.00	1,560,000	14,040,000	6,922,870
Johnson David Michael	Director	Nov 08 '23	Buy	7.30	20,000	146,000	75,000
Johnson David Michael	Director	Nov 08 '23	Buy	7.30	9,601	70,087	135,667
Johnson David Michael	Director	Nov 07 '23	Buy	7.17	94,000	673,980	65,000
Johnson David Michael	Director	Nov 07 '23	Buy	7.17	76,000	544,920	126,066
Feder Julie B	Chief Financial Officer	Nov 06 '23	Option Exercise	2.74	3,900	10,686	73,500
de los Pinos Elisabet	See Remarks	Nov 06 '23	Option Exercise	2.74	3,800	10,412	184,740
de los Pinos Elisabet	See Remarks	Nov 06 '23	Sale	12.03	7,449	89,611	177,291
Feder Julie B	Chief Financial Officer	Nov 06 '23	Sale	12.07	3,900	47,054	69,600

Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform to treat tumors of high unmet need in ocular and urologic oncology. Its AU-011, a VDC candidate, is being developed for the first line treatment of primary choroidal melanoma, a rare disease with no drugs approved. The company also develops AU-011 in additional ocular oncology indications, including choroidal metastases. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.